Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9404722 | 0.83 | TDP1 (0.48) | ERN1ALDH1A1MAPT | |
| SCHEMBL6639987 | 0.79 | ERN1 (1.00) | ERN1ACMSD | |
| SCHEMBL7591430 | 0.79 | ERN1 (0.69) | ERN1KCNH2BACE1ACMSDPTPRC | |
| SCHEMBL3568658 | 0.77 | KCNH2 (1.00) | ERN1KCNH2BACE1ACMSDPTPRC | |
| SCHEMBL15009485 | 0.76 | ERN1 (0.76) | ERN1KCNH2BACE1ACMSDPTPRC | |
| SCHEMBL6091277 | 0.76 | ERN1 (0.68) | ERN1ALDH1A1CYP2A6 | |
| SCHEMBL992459 | 0.76 | ERN1 (0.53) | ERN1CHEK1CYP2A6CHEK2 | |
| SCHEMBL18717328 | 0.73 | KCNH2 (0.69) | ERN1KCNH2BACE1ACMSDPTPRC | |
| SCHEMBL3134647 | 0.73 | KCNH2 (0.69) | ERN1KCNH2BACE1ACMSDPTPRC | |
| SCHEMBL9910726 | 0.72 | KCNH2 (0.62) | ERN1KCNH2BACE1ACMSDPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | ERN1 1576/4885KCNH2 302/4885BACE1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.